Q-omics provides the consensus-scored RPL15P18 profile across patient tissues and cancer cell-line models. RPL15P18 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, RPL15P18 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, RPL15P18 RNA expression shows 10,881 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUSC, COAD, and ACC as cancer lineages where RPL15P18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL15P18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL15P18 survival associations across molecular data types. RPL15P18 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL15P18 RNA expression–survival associations across cancer types. High RPL15P18 expression shows unfavorable associations in ACC, LUAD, ESCA and SKCM, but favorable associations in LUSC and KIRC. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for RPL15P18 RNA expression.
This table summarizes RPL15P18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL15P18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL15P18 shows higher tumor expression in COAD, THCA, LUAD and LIHC. The COAD box plot shows higher RPL15P18 RNA expression in tumor versus normal tissue (log2 FC = +0.555, t-test p < 0.001).
This table shows molecular features associated with RPL15P18 in patient tissues and cancer cell lines. In patient samples, RPL15P18 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
